VYGR — Voyager Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSuper Stock

Annual income statement for Voyager Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	104	171	37.4	40.9	250
Selling / General / Administrative Expenses
Research And Development
Total Operating Expenses	156	144	111	91.7	128
Operating Profit	-51.7	27.4	-73.6	-50.8	122
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-43.6	36.7	-71.2	-46.4	134
Provision for Income Taxes
Net Income After Taxes	-43.6	36.7	-71.2	-46.4	132
Net Income Before Extraordinary Items
Net Income	-43.6	36.7	-71.2	-46.4	132
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-43.6	36.7	-71.2	-46.4	132
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.21	0.984	-1.82	-1.21	2.97